(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

    Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  NHrjS2NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHrqfG4zPTBxNUCwM|ExODBibl2= MXKyOE81QC95MjDo NYPlRWZkTE2VTx?= NVqxNm9UcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? NIjZVZkzPjdyN{i4NS=>
BCPAP NXzGb5h3S2WubDDWbYFjcWyrdImgRZN{[Xl? MYeyOVAwPTByL{GwNFAhdk1? NUPSXIdTOjRxNEivO|IhcA>? NVLpZ3JSTE2VTx?= NWOxUXFCcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? MkHjNlY4ODd6OEG=
K1  M4PJPWNmdGxiQ4njcIUhSXO|YYm= MknONlUxNzVyMD:xNFAxKG6P M{DJdlczKGh? MlzvSG1UVw>? NXXNT21v[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl MmfzNlY4ODd6OEG=
BCPAP NHrYUJpE\WyuIFP5Z4xmKEG|c3H5 MoDBNlUxNzVyMD:xNFAxKG6P NULMbIhqPzJiaB?= NIrSUWZFVVOR M{HofYFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= NVzUb4l{OjZ5MEe4PFE>
Hep3B MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGwMVExKM7:TR?= MWe1JIQ> NX64Zo1qTE2VTx?= Mo[3TWM2OD1yLkC4JO69VQ>? M2HRb|I3PTd3MU[3
HCCLM3 NIDhfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\neVAuOTBizszN MYK1JIQ> NXPI[npPTE2VTx?= NInKNFFKSzVyPUCuNVQh|ryP MkDmNlY2PzVzNke=
HuH7 M3TOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrOOI5tOC1zMDFOwG0> Mn;SOUBl Mnu2SG1UVw>? MlvVTWM2OD1yLkKxJO69VQ>? MYqyOlU4PTF4Nx?=
HepG2 M3TZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGwMVExKM7:TR?= MlXtOUBl MVvEUXNQ NGXKfnpKSzVyPUCuN|Qh|ryP MWiyOlU4PTF4Nx?=
SMMC7721 NWrvcpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzKNE0yOCEQvF2= NEHZS242KGR? MoDmSG1UVw>? NVTxXXpnUUN3ME2wMlQyKM7:TR?= NEPCcWgzPjV5NUG2Oy=>
BEL7402 NIDCNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M336[lAuOTBizszN NXfTXW46PSCm NEnNeVhFVVOR NEO0No5KSzVyPUCuOFch|ryP MYCyOlU4PTF4Nx?=
MHCC97H NFf2OZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO1RZcxNTFyIN88US=> NHnqepk2KGR? NIDBc5BFVVOR NF3afllKSzVyPUCuOFEh|ryP NVHF[4trOjZ3N{WxOlc>
Hep3B M{LoXGNmdGxiQ4njcIUhSXO|YYm= NETFO3gxNjFxMD61M|IvPSEQvF2= M{PTV|Q5KGh? MoTjSG1UVw>? NWjCSmM5dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi NVnpc2h5OjZ3N{WxOlc>
HCCLM3 NITPd|hE\WyuIFP5Z4xmKEG|c3H5 NWTESWF5OC5zL{CuOU8zNjVizszN MVy0PEBp NILBXHBFVVOR M2flOYxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? MojvNlY2PzVzNke=
Hep3B MnHrRZBweHSxc3nzJGF{e2G7 M17zb|AvOS9yLkWvNk42KM7:TR?= M{HQVFQ5KGh? MYTEUXNQ NV2zV21E[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bTDmdo9uKG2rdH;jbI9v\HKrYR?= NX;1dlNEOjZ3N{WxOlc>
HCCLM3 MXHBdI9xfG:|aYOgRZN{[Xl? NWrEU5BNOC5zL{CuOU8zNjVizszN NGXsN|I1QCCq NUfkXZBPTE2VTx?= MV;hZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli Ml32NlY2PzVzNke=
A549 NIPlTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKyNE4yNTFyIN88US=> MYO3NkBp NX63cXF7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{eyTVI3PDF3MkK1
H157 NGG2dZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorPNE4yNTFyIN88US=> NEDKTYY4OiCq M1G2WYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVSyOlQyPTJ{NR?=
H1299 M3vve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XZbVAvOS1zMDFOwG0> NXnQSXFYPzJiaB?= NFPjdpBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mor3NlY1OTV{MkW=
A549 NGfXb4tHfW6ldHnvckBCe3OjeR?= NHziWVEyNzJwNT:1JO69VQ>? Moj4NVIhcA>? Mk\kxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? M3jTUFI3PDF3MkK1
H1299 NWPuUHNrTnWwY4Tpc44hSXO|YYm= MVKxM|IvPS93IN88US=> MkjsNVIhcA>? MVhCpJdm[WuueTDk[YNz\WG|ZXSgRoNtNTJibHX2[Yx{ MWeyOlQyPTJ{NR?=
H157 MoO1SpVv[3Srb36gRZN{[Xl? NHPwWXMyNzJwNT:1JO69VQ>? NXq1S3NjOTJiaB?= NEW1dnll\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= Mlq1NlY1OTV{MkW=
H1299 NYDNfmNxTnWwY4Tpc44hSXO|YYm= NGHEWmQyNzJwNT:1JO69VQ>? NXvBZXpxOTJiaB?= MYDk[YNz\WG|ZXSgSHI1KGW6cILld5Nqd25? M3;UdlI3PDF3MkK1
C8161 Mn3jR4VtdCCYaXHibYxqfHliQYPzZZk> NYrs[3hqOC1{IN88US=> MmPsOEBl MlmxSG1UVw>? NFXCOWJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmnqNlY{QTd{MkO=
Mel285 Mk\UR4VtdCCYaXHibYxqfHliQYPzZZk> MU[wMVIh|ryP MmDoOEBl NX;FN3hvTE2VTx?= NXPSWXY{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mln5NlY{QTd{MkO=
Mel290 NYH3W4lES2WubDDWbYFjcWyrdImgRZN{[Xl? MlWzNE0zKM7:TR?= NET5THE1KGR? MXXEUXNQ MYnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NY\icY5mOjZ|OUeyNlM>
92.1 NUXwcJlZS2WubDDWbYFjcWyrdImgRZN{[Xl? M2TkNVAuOiEQvF2= MmfaOEBl MnLKSG1UVw>? NVzBO5Zo\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUTuWVlpOjZ|OUeyNlM>
Omm1.3 MnOzR4VtdCCYaXHibYxqfHliQYPzZZk> MoPnNE0zKM7:TR?= NEfjd5Y1KGR? MWLEUXNQ MUTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mo\wNlY{QTd{MkO=
Mel202 M135WGNmdGxiVnnhZoltcXS7IFHzd4F6 NInsPYUxNTJizszN MWS0JIQ> NIfnZ5RFVVOR NFPpd3Vl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGrGcpkzPjN7N{KyNy=>
Mel270 NEPZeVBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX;oW3RWOC1{IN88US=> MkmwOEBl MWXEUXNQ MUDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{DmfFI3Ozl5MkKz
Omm1 M4OwR2NmdGxiVnnhZoltcXS7IFHzd4F6 MYCwMVIh|ryP NFzQOHI1KGR? M3W2[2ROW09? NIe0bW9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXHBOWJ[OjZ|OUeyNlM>
92.1 NWLCVlZCSXCxcITvd4l{KEG|c3H5 NFyxZVY2ODBibl2= M2TXWlQ5KGh? NV:3WpJwTE2VTx?= MlHTbY5lfWOnczDhdI9xfG:|aYO= MVKyOlM6PzJ{Mx?=
Omm1.3 NFrx[5lCeG:ydH;zbZMhSXO|YYm= MlLwOVAxKG6P MoTWOFghcA>? NYLNb|JWTE2VTx?= MnvubY5lfWOnczDhdI9xfG:|aYO= NWjZdG4{OjZ|OUeyNlM>
92.1 NYXiR3RCS2WubDDDfYNt\SCDc4PhfS=> M1jTN|UxOCCwTR?= NHe4UIozPC92OD:3NkBp M1HVfmROW09? MVjpcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? NVzkbmRSOjZ|OUeyNlM>
Omm1.3 M1zGVWNmdGxiQ4njcIUhSXO|YYm= M2[1O|UxOCCwTR?= NHfCelMzPC92OD:3NkBp NWT5dFZPTE2VTx?= NF7jSGlqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= NYTzW5NKOjZ|OUeyNlM>
A549 NYTjW4k4TnWwY4Tpc44hSXO|YYm= NGnCbY4yODBxNECwM|ExODBibl2= MlrCNlQhcA>? M2jZPJVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? M4HzbVI3OjF{MUm5
MCF-7 NYDHVZJQTnWwY4Tpc44hSXO|YYm= NFfxNocyODBxNECwM|ExODBibl2= NF;OXJYzPCCq MYj1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy MUOyOlIyOjF7OR?=
HEK293 NYjiV3V4TnWwY4Tpc44hSXO|YYm= MYGxNFAwPDByL{GwNFAhdk1? Ml\2NlQhcA>? Mmq4eZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? NWTTfYZHOjZ{MUKxPVk>
858 M4TEW2NmdGxiVnnhZoltcXS7IFHzd4F6 NGLt[4oxNTFizszN NYn5UlREPSCm Mm\USG1UVw>? NVrpd|VE\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkmxNlYzODZ|M{O=
DDR2L63V MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2LzS|AuOSEQvF2= NF7V[Wk2KGR? NXTBSopoTE2VTx?= NXKxbpI{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFTNeZIzPjJyNkOzNy=>
BE(2)-C M{T5NWNmdGxiVnnhZoltcXS7IFHzd4F6 NXLxd2tDOSEQvF2= MX6xMVQh\A>? NEPZSoJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NEnoSXAzPjB4N{S2OC=>
IMR-32 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MojsNUDPxE1? MV6xMVQh\A>? Mnu4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NV7Mc5I{OjZyNke0OlQ>
JF MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NILxS5oyKM7:TR?= MorlNU01KGR? MmPu[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NFTQSmozPjB4N{S2OC=>
BE(2)-M17 NFPRV5JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUTIdIxKOSEQvF2= NET6PZoyNTRiZB?= NYOzTGZ6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NXrDWJoxOjZyNke0OlQ>
SK-N-SH M4TPSmNmdGxiVnnhZoltcXS7IFHzd4F6 NE\kWnMyKM7:TR?= MX6xMVQh\A>? NXy3TXVP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NXO5bYd2OjZyNke0OlQ>
SK-N-DZ  MmTxR4VtdCCYaXHibYxqfHliQYPzZZk> M3rBcVEh|ryP M2DafVEuPCCm NFXpcItl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MWWyOlA3PzR4NB?=
HMC-1.1  MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS1MVUxODBibl2= M1HYNVQ5KGh? M1i1XmROW09? NVjnVlBOcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGLzW5YzPjB3NUOwNy=>
HMC-1.2 M{PheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nHWVUuPTByMDDuUS=> MmTyOFghcA>? NFi0cm9FVVOR MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVKyOlA2PTNyMx?=
ROSA KIT WT  M1Hm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7IOU02ODByIH7N NF23ZYk1QCCq MoP6SG1UVw>? NGLhSZdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWfPWXoyOjZyNUWzNFM>
ROSA KIT D816V MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fBSVUuPTByMDDuUS=> M1XGVVQ5KGh? NE\rTJpFVVOR NWnPTXVIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmPuNlYxPTV|MEO=
HMC-1.1  NWLH[G5[SXCxcITvd4l{KEG|c3H5 NV7zSIZbOjByLUWwNFAhdk1? Mlm2OFghcA>? MkG0SG1UVw>? MXvpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEXhSFIzPjB3NUOwNy=>
HMC-1.2 M{fR[mFxd3C2b4Ppd{BCe3OjeR?= NHX0PVMzODBvNUCwNEBvVQ>? NVS3VVBYPDhiaB?= NFTk[YNFVVOR NEOxUoFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGLJfWwzPjB3NUOwNy=>
ROSA KIT WT  NFnQUZFCeG:ydH;zbZMhSXO|YYm= Mn\zNlAxNTVyMECgcm0> NX;2RWVuPDhiaB?= MorkSG1UVw>? NWrydm1UcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX7FNZhSOjZyNUWzNFM>
ROSA KIT D816V NEi2NllCeG:ydH;zbZMhSXO|YYm= NIXad3EzODBvNUCwNEBvVQ>? NES3To41QCCq NI[0[IFFVVOR M4\p[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXvFSYpmOjZyNUWzNFM>
494H MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTNT4g4OiCq MVHEUXNQ NYq4eXk2UUN3ME2wMlEzOsLzMD6wNFQh|ryP MWGyOVk1PDV4Nh?=
493H MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrMO|IhcA>? NW\Le2lPTE2VTx?= NFHtWWpKSzVyPUCuNFQ4yrFyLkCwPUDPxE1? M{Hje|I2QTR2NU[2
716H MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS1bZhHPzJiaB?= MX3EUXNQ M1PrV2lEPTB;MD6yNVLDuTBwMEO0JO69VQ>? MUCyOVk1PDV4Nh?=
148I NE\PS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jkUlczKGh? M3TJXmROW09? NF:1WZRKSzVyPUCuNlg1yrFyLkCzOUDPxE1? MnPzNlU6PDR3Nk[=
98Sc NUm2[|N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUmwZmlHPzJiaB?= MkP5SG1UVw>? M2Lnc2lEPTB;MD6xNVXDuTBwMEC0JO69VQ>? NULXVoVJOjV7NES1OlY>
89R NGizb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:3NkBp MmjGSG1UVw>? M1\ZcmlEPTB;MD6xNlbDuTBwMECzJO69VQ>? M2GzXVI2QTR2NU[2
494L NWnFS5NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf5Z204OiCq M3;0e2ROW09? Mn7ETWM2OD1yLkOxO:KyOC5yMUKg{txO MXOyOVk1PDV4Nh?=
493L MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:3O|IhcA>? Mk\uSG1UVw>? NVTPenpqUUN3ME2wMlA2OMLzMD6wNVEh|ryP NVT3TllTOjV7NES1OlY>
148L M2LoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPhWWhrPzJiaB?= MXLEUXNQ NHjC[Y5KSzVyPUCuNVQ3yrFyLkCxO{DPxE1? MVWyOVk1PDV4Nh?=
98L MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vQb|czKGh? NY[0PG9KTE2VTx?= NVzMZVR{UUN3ME2wMlMxQcLzMD6wNlkh|ryP M{LVdVI2QTR2NU[2
OS17 M1zVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nRRlczKGh? NWPF[ZNGTE2VTx?= MV;JR|UxRTBwMEe5xtExNjByMzFOwG0> M1jLXFI2QTR2NU[2
OS9 NYLBOY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDCOHV6PzJiaB?= NXTzbG5CTE2VTx?= M376[2lEPTB;MD60NFbDuTBwMEK4JO69VQ>? NXn0WotKOjV7NES1OlY>
MG63 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3xTIE4OiCq MVLEUXNQ M2\pVWlEPTB;MD6xNVTDuTBwMEK1JO69VQ>? M{GzVVI2QTR2NU[2
SAOS2 M2i0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG0SnE4OiCq NYK0Umc6TE2VTx?= NV:4Znd7UUN3ME2wMlIyP8LzMD6wNFMh|ryP M1v6fVI2QTR2NU[2
U2OS MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;lPIE4OiCq M3\iW2ROW09? MUDJR|UxRTBwMUm4xtExNjByODFOwG0> Moj5NlU6PDR3Nk[=
SJSA-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjzW|M2PzJiaB?= NYLuW2hXTE2VTx?= M164N2lEPTB;MD6xNFDDuTBwMEGwJO69VQ>? MUiyOVk1PDV4Nh?=
494H MUXBdI9xfG:|aYOgRZN{[Xl? MlnDNE4zPS9yLkWvNU4xKM7:TR?= MUOyOEBp MVTEUXNQ NI\FUlBqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? MVyyOVk1PDV4Nh?=
148I MUHBdI9xfG:|aYOgRZN{[Xl? M3L5clAvOjVxMD61M|EvOCEQvF2= M13tXlI1KGh? MXLEUXNQ M{L1WYlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NX\KfYhzOjV7NES1OlY>
OS17 NE\X[2lCeG:ydH;zbZMhSXO|YYm= MW[wMlI2NzBwNT:xMlAh|ryP NWDMUW5UOjRiaB?= NGDaeIJFVVOR M2XkVIlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NH3HSVkzPTl2NEW2Oi=>
494H M{fFcmFxd3C2b4Ppd{BCe3OjeR?= MnHjNgKBkc7:TR?= M3jYU|Q5KGh? NUDtTYlLTE2VTx?= MWHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= MVKyOVk1PDV4Nh?=
148I MmTrRZBweHSxc3nzJGF{e2G7 MlrqNgKBkc7:TR?= MX20PEBp NInTcIlFVVOR NUe3WpRDcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MX2yOVk1PDV4Nh?=
OS17 NFr0N29CeG:ydH;zbZMhSXO|YYm= NE\1VVAy6oDLzszN MkfvOFghcA>? M{\JVWROW09? M4TEb4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> MmrXNlU6PDR3Nk[=
MOLM13 NEDMTIlCeG:ydH;zbZMhSXO|YYm= NYnrOoxvOjVyIH7N MmrFOFghcA>? M4jqSWROW09? MmnybY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk NYDjO|ZiOjVyNUO4NlU>
MV4-11  NULtO5E2SXCxcITvd4l{KEG|c3H5 NUG1RZFIOjVyIH7N MU[0PEBp NGW0UJdFVVOR M2Cx[4lv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= M1\FdlI2ODV|OEK1
MOLM13 NVj4SZRjTnWwY4Tpc44hSXO|YYm= NGHLNnMzPTBibl2= NFW4c2kzPCCq MXnEUXNQ Mlnz[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS NW\xbIJ5OjVyNUO4NlU>
MV4-11  NYC2cYN3TnWwY4Tpc44hSXO|YYm= NU[yN3lsOjVyIH7N MXuyOEBp NXrOV5hSTE2VTx?= MoLx[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS MXKyOVA2Ozh{NR?=
MOLM13 MmThRZBweHSxc3nzJGF{e2G7 M1PTWFI2OCCwTR?= NYXPXoM5PDhiaB?= Mmm3SG1UVw>? MVLpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheG:wYYTpcolj MYGyOVA2Ozh{NR?=
MV4-11  NYmye|JsSXCxcITvd4l{KEG|c3H5 Mnj4NlUxKG6P NVvx[|VkPDhiaB?= NVW2NYhPTE2VTx?= M1G3cIlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? NUf3Z4lKOjVyNUO4NlU>
Hela NXzuWHFIS2WubDDWbYFjcWyrdImgRZN{[Xl? NYnHfG1sOC13MECgcm0> NELrXZA4OiCq MonaSG1UVw>? Mlv0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1v5PFI2ODB7Mkm1
HBL-1 NEHnPYhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXWwMVUxOCCwTR?= M2fUc|czKGh? M{\pdWROW09? NF3xWFJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1HzOFI2ODB7Mkm1
HLY-1 MkHRR4VtdCCYaXHibYxqfHliQYPzZZk> NXPheWRrOC13MECgcm0> MVi3NkBp MWjEUXNQ NEjXWG1l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1vp[VI2ODB7Mkm1
OCI-Ly3 NVz6b5hVS2WubDDWbYFjcWyrdImgRZN{[Xl? Mm[2NE02ODBibl2= M4TWd|czKGh? M3;MU2ROW09? M3TqWYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXyyOVAxQTJ7NR?=
OCI-Ly10 M2rpOWNmdGxiVnnhZoltcXS7IFHzd4F6 NX;wWGhEOC13MECgcm0> M17vWVczKGh? M3H0OmROW09? NFmwdmdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3zCRlI2ODB7Mkm1
SU-DHL-4 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHrTTnUxNTVyMDDuUS=> MlPYO|IhcA>? NET5[XpFVVOR MmnS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NH21WIczPTByOUK5OS=>
SU-DHL-5 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGjTSFUxNTVyMDDuUS=> Mn\hO|IhcA>? NX3BR4pbTE2VTx?= MlXv[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2i2PVI2ODB7Mkm1
SU-DHL-6 NGfqRYFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mo\hNE02ODBibl2= M2fleVczKGh? MXPEUXNQ Mojj[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4O4RVI2ODB7Mkm1
SU-DHL-10 NEHhNlBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYKwMVUxOCCwTR?= MVq3NkBp MkHmSG1UVw>? MVzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXmyOVAxQTJ7NR?=
RC-K8 M3z0fGNmdGxiVnnhZoltcXS7IFHzd4F6 MnHGNE02ODBibl2= MX63NkBp NEPQXGNFVVOR MU\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1TWeVI2ODB7Mkm1
OCI-Ly8 NIXvdJpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4Xjd|AuPTByIH7N NH\QbVg4OiCq MULEUXNQ MkH2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NI\HbHgzPTByOUK5OS=>
OCL-Ly18 NVqzVok6S2WubDDWbYFjcWyrdImgRZN{[Xl? NF63UmMxNTVyMDDuUS=> NEnkSJk4OiCq MV\EUXNQ Mm[5[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIDlbYIzPTByOUK5OS=>
OCI-Ly3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHROZEyPzJxMkWwM|UxOCCwTR?= NUPvXHFMOi95IHS= MnfkSG1UVw>? MUjpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NXnENINmOjVyMEmyPVU>
OCI-Ly8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTOR5EyPzJxMkWwM|UxOCCwTR?= NELuZZMzNzdiZB?= NUjzUmJuTE2VTx?= MYjpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NYOzSm9ZOjVyMEmyPVU>
SU-DHL-4 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HlSVE4Oi9{NUCvOVAxKG6P M3;uelIwPyCm M1XIRmROW09? MY\pcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NEftNWIzPTByOUK5OS=>
SU-DHL-10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnYNVczNzJ3MD:1NFAhdk1? M2LFZlIwPyCm NHuyb2FFVVOR MXfpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi Ml;WNlUxODl{OUW=
OCI-Ly3 NFTZS4NCeG:ydH;zbZMhSXO|YYm= Ml;KNVczNzJ3MDDuUS=> NHiwcJg4\A>? M3uyRmROW09? NEH1OHJqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> MUeyOVAxQTJ7NR?=
OCI-Ly8 NILPU|JCeG:ydH;zbZMhSXO|YYm= NUHMOm1QOTd{L{K1NEBvVQ>? NGrVdW04\A>? NIq1bGdFVVOR M{T6d4lv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> NHW1TXczPTByOUK5OS=>
SU-DHL-4 MVjBdI9xfG:|aYOgRZN{[Xl? M2KybVE4Oi9{NUCgcm0> NIrDS5E4\A>? NYj6OGRHTE2VTx?= MnvzbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MmnzNlUxODl{OUW=
SU-DHL-10 MoLDRZBweHSxc3nzJGF{e2G7 Mk\1NVczNzJ3MDDuUS=> MXy3[C=> NFnFTnZFVVOR NXrJNG9KcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 MWSyOVAxQTJ7NR?=

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID